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OBJECTIVES We sought to define the clinical and long-term prognostic implications of autoantibodies that
act against the second extracellular loop of beta1-adrenergic receptors (ARs) in patients with
idiopathic dilated cardiomyopathy (IDC).
BACKGROUND Although autoantibodies directed against various domains of beta-ARs are found in patients
with IDC, only a subgroup against the second extracellular domain of beta1-ARs exerts
intrinsic sympathomimetic-like actions on human beta-ARs. It is suggested that the
autoantibodies take part in the pathophysiology of IDC and may affect long-term prognosis
of patients with this disorder.
METHODS Sera from 104 patients with IDC were screened for autoantibodies that act against the second
extracellular loop of beta1-ARs by enzyme-linked immunosorbent assay, using a synthetic
peptide corresponding to the domain. Relations of the autoantibodies to clinical variables and
long-term prognosis were assessed by multivariate analysis.
RESULTS Autoantibodies were detected in 40 patients (38%). Multifocal ventricular premature
contractions (p , 0.01) and ventricular tachycardia (VT; p , 0.01) were more common in
autoantibody-positive than in autoantibody-negative patients, although no differences in
cardiac function or neurohormonal levels were demonstrated. The presence of autoantibodies
(p 5 0.001) and a low left ventricular ejection fraction (LVEF ,30%; p 5 0.02) were
independent predictors of VT. Sudden death was independently predicted by the presence of
autoantibodies (p 5 0.03), as well as by LVEF ,30% (p 5 0.01), whereas total mortality was
predicted only by LVEF ,30% (p 5 0.001).
CONCLUSIONS Autoantibodies directed against the second extracellular loop of beta1-ARs were closely
related to serious ventricular arrhythmias in patients with IDC, and the presence of
autoantibodies independently predicted sudden death. These autoantibodies may contribute
to electrical instability in patients with IDC. (J Am Coll Cardiol 2001;37:418–24) © 2001
by the American College of Cardiology
Autoantibodies that act against beta1-adrenergic receptors
(ARs) can be detected in ;30% to 50% of patients with
idiopathic dilated cardiomyopathy (IDC) (1–4). These
autoantibodies are directed against various domains of
beta-ARs as an epitope (1–4). Among them, only a sub-
group of autoantibodies directed against the second extra-
cellular domain of beta1-ARs has been shown to exert
agonist-like actions on human beta-ARs, inhibiting radio-
ligand binding and enhancing receptor-mediated signaling
in vitro (4). These results suggest that autoantibodies,
indeed, take part in the pathophysiology of IDC and may
affect the long-term prognosis of patients with this disorder.
Immunoapheresis to remove autoantibodies against
beta1-ARs from the blood has ameliorated symptoms and
improved hemodynamic variables in patients with IDC (5).
In contrast, a high prevalence of autoantibodies that act
against beta-ARs has been found among patients with
primary electrical cardiac abnormalities (6). Several studies
have reported relations between clinical variables and the
autoantibodies in IDC (4,7). However, the characteristics of
a subset of patients with IDC who have the autoantibodies
have not been subjected to multivariate analysis to assess
their interactions. We used this analytic method to better
characterize patients with IDC with autoantibodies directed
against the second extracellular loop of beta1-ARs.
METHODS
Study patients. One hundred four patients with IDC who
were clinically stable with conventional therapy, including
digitalis glycosides, diuretics, angiotensin-converting en-
zyme inhibitors or beta-blockers, were treated in our clinic
and were recruited to participate in the present study
between 1995 and 1999. The patients’ mean age was 56 6
14 years. The diagnosis of IDC was based on World Health
Organization/International Society and Federation of Car-
diology criteria established in 1995 (8). A left ventricular
ejection fraction (LVEF) ,55% was confirmed by radionu-
clide ventriculography (mean LVEF 30 6 10%). Coronary
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angiography was performed in 87 patients (84%), and
myocardial biopsy was performed in 78 patients (75%).
Patients with .50% stenosis of the major coronary arteries,
myocarditis or one of the other specific cardiomyopathies
were excluded. The study protocol was approved by an
institutional Review Committee, and all patients gave writ-
ten, informed consent to participate in the present study.
Antibody detection. The autoantibodies of interest were
measured in patient sera with an enzyme-linked immu-
nosorbent assay (ELISA), using a synthetic peptide corre-
sponding to the putative sequence of the second extracellu-
lar loop of human beta1-ARs (amino acid sequence number,
197 to 222; His-Trp-Trp-Arg-Ala-Glu-Ser-Asp-Glu-Ala-
Arg-Arg-Cys-Tyr-Asn-Asp-Pro-Lys-Cys-Cys-Asp-Phe-
Val-Thr-Asn-Arg). Briefly, 50 ml of peptide (50 mg/ml in
0.1 mol/liter Na2CO3) was coated on microtiter plates. The
wells were then saturated with phosphate-buffered saline
(PBS), including 3% skim milk, 0.1% polysorbate-20
(Tween-20) and 0.01% thimerosal (Merthiolate) (PMT).
Fifty microliters of patient serum dilutions beginning at
1:20 were then added to the coated and saturated microtiter
plates. After the wells were washed three times with PBS,
an affinity-purified biotinylated rabbit anti-human immu-
noglobulin G antibody solution diluted 1:1000 in PMT was
allowed to react for 1 h. After another three washes, bound
biotinylated antibodies were detected using streptavidin
peroxidase (1 mg/ml), and as substrates H2O2 (2.5 mmol/
liter) with 2,29-azino-diethylbenzthiazoline sulfonic acid (2
mmol/liter). After 30 min, optical densities were deter-
mined at 405 nm in an ELISA reader. Positivity was
defined as 2.5 times the background density.
Clinical variables. Clinical variables, including findings
from ultrasonic echocardiography and Holter monitoring,
were recorded for all patients within one month of serum
sampling for measurement of autoantibodies. Echocardiog-
raphy was performed to assess left ventricular end-diastolic
dimensions, end-systolic dimensions and fractional short-
ening. The Holter electrocardiogram (ECG) was analyzed
by using the Marquette system (SXP 8000 or MARS 8000,
Marquette Medical Systems Inc., Milwaukee, Wisconsin)
to assess the total number of supraventricular premature
contractions (SVPCs) and ventricular premature contrac-
tions (VPCs). The morphology of VPC, presence of ven-
tricular tachycardia (VT), maximal number of runs of VT,
longest VT duration and fastest VT rate were examined.
Data were averaged from two or more sets of recordings.
Ventricular tachycardia was defined as a run of three or
more consecutive VPCs with a heart rate $100 beats/min,
which was noted in at least one of the recordings. Further-
more, VT lasting $3 s or VT with a maximal rate $165
beats/min was defined as high risk VT, according to each
median value, as previously described (9). Blood samples for
measurement of plasma norepinephrine and serum potas-
sium were collected from a peripheral vein after the patient
had rested in the supine position for at least 20 min.
Patient follow-up. The patients studied were followed for
a mean of 31 months (range 0.2 to 52.5). Deaths were
classified as follows: sudden death was defined as death
within 1 h without previous worsening of symptoms of heart
failure. Unexpected death occurring during sleep was con-
sidered to be sudden when patients were found dead in the
morning by family members sharing the same room. We
generally classified other unwitnessed deaths as unknown.
When death occurred as a consequence of progressive
deterioration of heart failure, acute pulmonary edema or
cardiogenic shock, we classified it as due to pump failure
(10).
Statistical analyses. Data are expressed as the mean
value 6 SD. Comparison between two groups was per-
formed by using the nonpaired t test or the nonparametric
means test for continuous variables and by the chi-square
test for discrete variables. Logistic regression analysis was
used to assess predictors of VT. Twelve variables, including
those with p values ,0.10 by univariate analyses, were
further assessed by multivariate logistic regression analysis.
Kaplan-Meier survival curves for cardiac mortality, sudden
death and pump failure death were calculated according to
presence or absence of autoantibodies, and the differences
were analyzed by the log-rank test. Long-term prognosis
was assessed by using the Cox proportional hazards model.
Statistical significance was set at p , 0.05. StatView 5.0
software (SAS Institute Inc., Cary, North Carolina) was
used for statistical analyses.
RESULTS
Patient characteristics and autoantibodies. Autoantibod-
ies against the second extracellular loop of beta1-ARs were
detected in 40 patients in our study group (38%). No
difference was noted for age, duration of illness, gender,
New York Heart Association (NYHA) functional class,
concomitant medications, cardiac function or plasma nor-
epinephrine levels between autoantibody-positive and
autoantibody-negative patients (Table 1).
Holter ECG findings are summarized in Table 2. No
difference was evident in the number of SVPCs or VPCs
between the autoantibody-positive and autoantibody-
negative patients. The presence of VT was more common in
the autoantibody-positive than in autoantibody-negative
Abbreviations and Acronyms
AR 5 adrenergic receptor
cAMP 5 cyclic adenosine monophosphate
ECG 5 electrocardiogram
ELISA 5 enzyme-linked immunosorbent assay
IDC 5 idiopathic dilated cardiomyopathy
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PBS 5 phosphate-buffered saline
SVPC 5 supraventricular premature contractions
VPC 5 ventricular premature contractions
VT 5 ventricular tachycardia
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patients, with multifocal VPCs being predominant. The
maximal numbers of runs of VT were similar between the
two groups, although the maximal heart rate during VT was
greater in autoantibody-positive than in autoantibody-
negative patients.
Determinants of VT. Univariate analyses were performed
for the 17 variables listed in Table 3, which showed that the
presence of autoantibodies, LVEF ,30% and the use of
diuretics were related to the presence of VT (Table 3).
Multivariate logistic regression analysis showed the presence
of autoantibodies to be the strongest independent predictor
of overall VT. Poor left ventricular function (LVEF ,30%)
also independently predicted overall VT. For high risk VT,
however, the presence of autoantibodies was the sole inde-
pendent predictor (Table 4).
Subgroups representing autoantibody-positive and
autoantibody-negative patients were analyzed further with
regard to the presence of VT. In autoantibody-positive
patients, no additional factor significantly predicted overall
VT, although the use of beta-blockers was a negative
predictor of high risk VT (odds ratio [OR] 0.11, 95%
confidence interval [CI] 0.01 to 0.89; p 5 0.04). For
autoantibody-negative patients, LVEF ,30% was an inde-
pendent predictor of overall VT (OR 7.28, 95% CI 1.26 to
42.18; p 5 0.03), but no significant predictor of high risk
VT was identified (data not shown).
Table 1. Clinical Characteristics of the Study Group (n 5 104)
Ab-Negative
Patients
(n 5 64)
Ab-Positive
Patients
(n 5 40)
p
Value
Age (years) 55 6 14 59 6 14 NS
Duration of illness (months) 77 6 45 74 6 57 NS
Gender (male/female) 53/11 29/11 NS
NYHA functional class (I/II/III/IV) 29/24/8/3 24/14/2/0 NS
Concomitant medications
Diuretics (%) 38 (59%) 20 (50%) NS
Digitalis (%) 35 (55%) 26 (65%) NS
ACE inhibitors (%) 37 (58%) 20 (50%) NS
Beta-blockers (%) 16 (25%) 12 (30%) NS
Calcium antagonists (%) 13 (20%) 7 (18%) NS
Antiarrhythmics (%) 14 (22%) 6 (15%) NS
Nitrates (%) 3 (5%) 2 (5%) NS
Anticoagulants (%) 31 (48%) 15 (38%) NS
Antiplatelets (%) 12 (19%) 12 (30%) NS
LVEDD (mm) 61 6 11 60 6 11 NS
LVESD (mm) 50 6 13 47 6 14 NS
LVFS (%) 20 6 9 23 6 11 NS
LVEF (%) 31 6 9 30 6 10 NS
Serum potassium (mEq/liter) 4.2 6 0.4 4.1 6 0.3 NS
PNE (pg/ml) 423 6 334 420 6 208 NS
Data are presented as the mean value 6 SD or number (%) of patients.
Ab 5 autoantibody; ACE 5 angiotensin-converting enzyme; LVEDD 5 left ventricular end-diastolic dimension; LVEF 5
left ventricular ejection fraction; LVESD 5 left ventricular end-systolic dimension; LVFS 5 left ventricular fractional
shortening; NYHA 5 New York Heart Association; PNE 5 plasma norepinephrine.
Table 2. Holter Electrocardiographic Findings
Ab-Negative
Patients
(n 5 64)
Ab-Positive
Patients
(n 5 40)
p
Value
Atrial fibrillation (%) 16 (25%) 12 (30%) NS
SVPCs (no./day) 514 6 1,340 399 6 1,146 NS
VPCs (no./day) 2,536 6 5,340 1,652 6 3,004 NS
Multiform VPCs (%) 43 (67%) 36 (90%) , 0.01
Presence of VT (%) 22 (34%) 26 (65%) , 0.01
Maximal runs of VT
(beats)
7 6 4 7 6 4 NS
Longest VT
duration (s)
2.6 6 1.2 2.4 6 1.2 NS
Fastest VT rate
(beats/min)
156 6 24 178 6 28 , 0.05
Data are presented as the mean value 6 SD or number (%) of patients.
Ab 5 autoantibody; SVPCs 5 supraventricular premature contractions; VPCs 5
ventricular premature contractions; VT 5 ventricular tachycardia.
Table 3. Univariate Predictors of Ventricular Tachycardia
Patients
With VT (%)
p
Value
Presence of autoantibodies (n 5 40) 26 (65) 0.0028
Age $60 years (n 5 45) 24 (53) 0.2009
Female gender (n 5 22) 11 (50) 0.6839
NYHA functional class $II (n 5 51) 22 (43) 0.5452
LVEF ,30% (n 5 50) 31 (62) 0.0022
PNE $400 pg/ml (n 5 50) 28 (56) 0.0541
Serum potassium ,4.0 mEq/liter (n 5 25) 12 (48) 0.8318
Atrial fibrillation (n 5 28) 12 (43) 0.6825
Diuretics (n 5 58) 33 (57) 0.0147
Digitalis (n 5 61) 30 (49) 0.4613
ACE inhibitors (n 5 57) 24 (42) 0.3624
Beta-blockers (n 5 28) 11 (39) 0.3950
Calcium antagonists (n 5 20) 7 (35) 0.2692
Antiarrhythmics (n 5 20) 7 (35) 0.2692
Nitrates (n 5 5) 1 (20) 0.2579
Anticoagulants (n 5 46) 25 (54) 0.1370
Antiplatelets (n 5 24) 14 (58) 0.1758
VT 5 ventricular tachycardia; other abbreviations as in Table 1.
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Determinants of cardiac mortality and sudden death.
After a mean follow-up period of 31 6 15 months, 82
patients (79%) were alive. The 22 deaths included 10
sudden deaths, 11 deaths due to pump failure and 1 death
due to cancer, with no deaths from unknown causes. Ten
cardiac deaths occurred in autoantibody-negative patients (3
sudden deaths and 7 pump failure deaths), and 11 cardiac
deaths occurred in autoantibody-positive patients (7 sudden
deaths and 4 pump failure deaths). Six patients without VT
had cardiac deaths (2 sudden deaths and 4 pump failure
deaths), and 15 cardiac deaths occurred in patients with VT
(8 sudden deaths and 7 pump failure deaths).
Figure 1 compares the Kaplan-Meier survival curves for
cardiac mortality, sudden death and pump failure death
according to the presence or absence of autoantibodies.
Sudden deaths were more common among autoantibody-
positive as compared with autoantibody-negative patients,
although no difference in overall cardiac mortality or pump
failure death was found between the two groups. Total
cardiac deaths (p 5 0.007 by the log-rank test) and sudden
Table 4. Multiple Logistic Regression Analysis
VT High Risk VT
OR 95% CI p Value OR 95% CI p Value
Presence of Ab 5.37 1.90–15.16 0.002 3.37 1.18–9.64 0.02
Age $60 years 0.95 0.34–2.60 0.91 0.95 0.33–2.79 0.93
LVEF ,30% 3.57 1.27–10.05 0.02 2.65 0.92–7.68 0.07
PNE $400 pg/ml 2.31 0.85–6.23 0.10 0.92 0.32–2.65 0.88
Serum potassium ,4.0 mEq/liter 0.98 0.31–3.08 0.97 1.21 0.38–3.88 0.75
Atrial fibrillation 0.48 0.16–1.43 0.19 2.00 0.67–6.01 0.21
Diuretics 2.70 0.87–8.37 0.09 1.74 0.55–5.57 0.35
Digitalis 1.31 0.45–3.87 0.62 1.37 0.44–4.30 0.59
ACE inhibitors 0.62 0.24–1.61 0.33 0.56 0.21–1.54 0.26
Beta-blockers 0.55 0.18–1.68 0.30 0.34 0.10–1.22 0.10
Calcium antagonists 0.69 0.20–2.45 0.57 0.41 0.09–1.84 0.25
Antiarrhythmics 0.41 0.11–1.56 0.19 1.01 0.25–4.12 0.99
CI 5 confidence interval; OR 5 odds ratio; VT 5 ventricular tachycardia; other abbreviations as in Table 1.
Figure 1. Kaplan-Meier survival curves by the presence or absence of autoantibodies directed against the second extracellular loop of beta1-ARs. (A) Survival
free from overall cardiac death. (B) Survival free from sudden death. (C) Survival free from pump failure death. Sudden death was more common in
autoantibody (Ab)-positive than in Ab-negative patients, although no difference in overall cardiac mortality or pump failure death was found between the
two groups.
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deaths (p 5 0.016) were more common in patients with VT
than in those without VT, although the occurrence of pump
failure death did not differ between the two groups. High
risk VT was associated with a higher incidence of cardiac
death in general (p 5 0.023) and of sudden death (p 5
0.016), as compared with low risk VT or no VT (data not
shown).
A Cox proportional hazards model for cardiac mortality
or sudden deaths was used to assess the significance of
autoantibodies and other clinical variables for long-term
outcome in patients with IDC. First, univariate analyses
with the proportional hazards model were performed for 18
variables, including the presence of VT, as well as for the
variables listed in Table 3, with the result that LVEF ,30%
and the presence of VT each were related to an increase in
overall cardiac mortality, whereas LVEF ,30%, the pres-
ence of VT and the presence of autoantibodies were related
to an increase in sudden death. Other variables were not
significantly related to either total cardiac mortality or
sudden death (p . 0.10). Accordingly, multivariate Cox
proportional hazards analysis was performed for the seven
variables listed in Table 5. Left ventricular ejection fraction
,30% was the only independent predictor of overall cardiac
mortality. For sudden death, the presence of autoantibodies
and LVEF ,30% were independent predictors. By multi-
variate analysis, the presence of overall VT or high risk VT
was not an independent predictor for either cardiac mortal-
ity or sudden death.
DISCUSSION
We characterized the clinical features of patients with
autoantibodies directed against the second extracellular loop
of beta1-ARs in a large group (n 5 104), demonstrating that
the presence of autoantibodies was associated with high risk
ventricular arrhythmias likely to result in sudden cardiac
death in patients with IDC.
Detection of autoantibodies directed against beta-
adrenergic receptors. A number of studies have shown
that autoantibodies directed against beta-ARs can be de-
tected in 26% to 95% of all patients with IDC, depending
on antibody detection methods (3,4). Jahns et al. (4)
demonstrated that autoantibodies selective for the amino
terminal or carboxy terminal domains of beta1-ARs and
those selective for the domains of beta2-ARs detected by
ELISA were nonspecific antibodies that were unable to
affect the function of native human receptors. In addition,
autoantibodies selective for the second extracellular loop of
beta2-ARs detected by ELISA were also nonspecific. Only
a subgroup of autoantibodies directed against the second
extracellular domain of beta1-ARs impaired receptor ligand
binding and enhanced receptor-mediated signaling in native
human beta-ARs. These findings suggest that functional
autoantibodies are detected by a peptide corresponding to
the second extracellular domain of beta1-ARs. In their
study, the positivity of ELISA was defined as the upper
limit of the 95% CI of healthy subjects, showing that 26%
of the autoantibodies directed against the second extracel-
lular loop of beta1-ARs, as detected by ELISA, were
nonspecific. In contrast, the present study defined positivity
as 2.5 times the background density. In the study by Jahns
et al. (4), immunoglobulin G preparations from patients
with IDC that showed .2.5 times the background density
in ELISA substantially enhanced cyclic adenosine mono-
phosphate (cAMP) production in sf9 cells expressing hu-
man beta1-ARs; there was a positive correlation between
immunoreactivity of ELISA and the increase in cAMP
production. Moreover, Magnusson et al. (1) confirmed that
the positive response of ELISA, according to the definition
in the present study, was a marker for the recognition of
human beta1-ARs by using Western blots and immunohis-
tochemistry. These observations support the fact that
ELISA, using a peptide corresponding to the second
extracellular loop of beta1-ARs, appropriately detects func-
tional autoantibodies by defining 2.5 times the background
density as a positive criterion.
Physiologic actions of autoantibodies. Affinity-purified
autoantibodies directed against the second extracellular loop
of beta1-ARs from patients with IDC were observed to
increase the beating frequency of cultured rat heart myo-
cytes, without inducing desensitization for more than 6 h; in
contrast, isoproterenol induced desensitization after stimu-
lation (2). In addition, these autoantibodies have been found
to inhibit radioligand binding to beta-ARs by decreasing
the numbers or the affinity and to enhance receptor-
Table 5. Univariate and Multivariate Cox Proportional Hazards Analyses
Total Mortality Sudden Death
Univariate
p Value
Multivariate Analysis
Univariate
p Value
Multivariate Analysis
Relative
Risk 95% CI
p
Value
Relative
Risk 95% CI
p
Value
Age $60 years 0.36 1.21 0.46–3.16 0.70 0.62 0.70 0.17–2.94 0.63
LVEF ,30% 0.001 9.01 2.23–30.30 0.001 0.02 15.39 1.78–125.0 0.01
PNE $400 pg/ml 0.38 1.65 0.61–4.53 0.33 0.89 1.29 0.29–5.71 0.74
Atrial fibrillation 0.22 2.39 0.95–6.06 0.07 0.33 2.98 0.79–11.36 0.11
Presence of VT 0.01 1.63 0.56–4.72 0.37 0.03 2.58 0.42–15.88 0.31
Beta-blockers 0.36 0.66 0.20–2.15 0.49 0.58 0.69 0.12–3.95 0.68
Presence of Ab 0.11 2.28 0.80–6.49 0.12 0.03 5.68 1.11–29.41 0.03
CI 5 confidence interval; VT 5 ventricular tachycardia; other abbreviations as in Table 1.
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mediated signaling by increasing both basal and
isoproterenol-stimulated cAMP levels in cells expressing
human beta-ARs (4). These phenomena induced by the
autoantibodies were completely abolished by the beta1-
selective antagonist, bisoprolol. These results show that the
autoantibodies exert a sustained intrinsic sympathomimetic-
like action through beta1 receptors. Long-term stimulation
of beta1-ARs by autoantibodies may induce electrophysi-
ologic instability through Ca21 overload. Ventricular ar-
rhythmias are induced by sympathetic stimulation through
triggered activity of both early and delayed afterdepolariza-
tions (11,12).
Clinical profile of autoantibody-positive patients with
IDC. Matsui et al. (7) examined autoantibodies directed
against the second extracellular loop of beta1-ARs in 28
patients with IDC; no difference in NYHA functional class
or LVEF was apparent between autoantibody-positive and
autoantibody-negative patients, although the issue of ven-
tricular arrhythmias was not considered. Chiale et al. (6)
reported a high prevalence of autoantibodies directed
against the domain of beta1-ARs and beta2-ARs among
patients with primary electrical cardiac abnormalities. These
autoantibodies were detected in 52.3% of patients with
ventricular arrhythmias. These authors suggested that auto-
antibodies found in patients with IDC were associated with
ventricular arrhythmias through beta1-ARs, but not
through beta2-ARs, as based on the functional test. This
finding is consistent with the previous reports that the
autoantibodies exert agonist-like actions through beta1-AR
in vitro (2,4). In contrast, ventricular arrhythmias may be
associated with cardiac dysfunction (13) or may be affected
by various clinical factors, including age, neurohormonal
levels and concomitant medications. A recent study reported
that the presence of autoantibodies directed against beta1-
ARs was associated with poorer left ventricular function in
patients with IDC (4), but clinical factors likely to affect
cardiac function may not be evenly distributed between
patient groups. Therefore, we performed multivariate anal-
ysis to assess the interactions between clinical factors in
large samples.
In our study, autoantibodies directed against the second
extracellular loop of beta1-ARs were associated with multi-
focal VPCs and the presence of VT, but not with the total
number of VPCs. The association may reflect electrophysi-
ologic actions of the autoantibodies. Ventricular tachycardia
was independently predicted by the presence of autoanti-
bodies and poor left ventricular function, whereas high risk
VT was predicted only by the presence of autoantibodies. In
other studies, complex ventricular arrhythmia was a major
risk factor for overall cardiac death (14,15) and sudden
death (16) in patients with IDC. Moreover, Szabo et al. (9)
documented that relatively persistent VT with a particularly
rapid rate predicted sudden cardiac death in patients with
left ventricular dysfunction, including IDC. In the present
study, the presence of VT was also associated with increased
overall cardiac mortality and sudden death, but VT was not
an independent predictor of these events. A previous study
concluded that the presence of VT in 24-h ECGs was an
independent predictor of sudden death in patients with
IDC (17). This discrepancy may be explained by the
presence of autoantibodies as an additional variable to
predict (on multivariate analysis) sudden death in the
present study. Multivariate analysis showed that the pres-
ence of autoantibodies was an independent predictor of
sudden death, as was left ventricular dysfunction; the latter
finding was in agreement with the previous studies
(14,15,18).
The beneficial effects of beta-blockers on symptoms,
cardiac function and overall survival in patients with heart
failure have been confirmed in large clinical trials (19–21).
In our study, the use of beta-blockers was associated with a
lower incidence of high risk VT, but not overall VT, in
autoantibody-positive patients, suggesting that beta-
blockers may attenuate electrophysiologic instability in-
duced by the autoantibodies, as demonstrated in vitro (2).
Recent clinical trials of beta-blockers have demonstrated
that these drugs can help to prevent sudden cardiac death in
patients with congestive heart failure (19–21). The autoan-
tibody hypothesis is one possible explanation for the de-
crease in sudden death in such patients.
Conclusions. The present study demonstrated that auto-
antibodies directed against the second extracellular loop of
beta1-ARs were closely related to serious ventricular ar-
rhythmias, but not to cardiac function or neurohormone
levels, in patients with IDC. The presence of these autoan-
tibodies and poor left ventricular function were independent
predictors of sudden cardiac death. Autoantibodies directed
against the second extracellular loop of beta1-ARs may be at
least partly responsible for electrical instability in patients
with IDC.
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